Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Time to Buy?

Key Points

• Genmab A/S shares gapped up, opening at $259.50, following a previous close of $249.25.
• The company reported $5.42 earnings per share (EPS) for the recent quarter, exceeding analysts' expectations of $3.99, with a net margin of 37.53%.
• Genmab A/S has a market capitalization of $17.15 billion and a beta of 0.90, indicating lower volatility compared to the market.

Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $249.25, but opened at $259.50. Genmab A/S shares last traded at $259.50, with a volume of 5 shares traded.

Genmab A/S Trading Up 5.8%

The firm has a market capitalization of $18.14 billion, a PE ratio of 13.78 and a beta of 0.90. The business has a 50 day moving average price of $225.22 and a 200-day moving average price of $212.41.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $949.06 million.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.